RecruitMe Clinical Trial

A Phase 1 Study to Evaluate the Safety and Tolerability of AB680 Combination Therapy in Participants with Gastrointestinal Malignancies
Study to Evaluate AB680 Combination Therapy in Participants with Gastrointestinal Malignancies
Sponsor:Arcus Biosciences, Inc.
Enrolling:Male and Female Patients
Minimum Age:18 years old
IRB Number:AAAS7260
U.S. Government ID:NCT04104672
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information:

This study is being done to see if potential new drugs, AB680 and AB122, can be safely given in combination with chemotherapy to study patients with pancreatic cancer. The standard chemotherapy treatments that will be given in combination with AB680 and AB122 are nab-paclitaxel and gemcitabine. AB680 and AB122 are are not approved by the United States Food and Drug Administration (U.S. FDA).

Do You Qualify?
Are you at least 18 years old?YesNo
Do you have confirmed metastatic pancreatic adenocarcinoma?YesNo
Have you had any prior treatment, including chemotherapy, biological therapy, or targeted therapy for metastatic disease?YesNo
Submit
Cancel
Investigator
Gulam Manji, MD, PhD
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Research Nurse Navigator
Email: cancerclinicaltrials@cumc.columbia.edu
Phone: 212-342-5162